$110,000.00 in Sales Expected for Celsion Co. (NASDAQ:CLSN) This Quarter

Equities analysts predict that Celsion Co. (NASDAQ:CLSNGet Rating) will post sales of $110,000.00 for the current quarter, according to Zacks. Three analysts have issued estimates for Celsion’s earnings, with the highest sales estimate coming in at $130,000.00 and the lowest estimate coming in at $100,000.00. Celsion posted sales of $130,000.00 during the same quarter last year, which would indicate a negative year over year growth rate of 15.4%. The business is scheduled to report its next quarterly earnings results on Monday, January 1st.

On average, analysts expect that Celsion will report full year sales of $500,000.00 for the current financial year. For the next fiscal year, analysts expect that the business will report sales of $500,000.00. Zacks’ sales calculations are an average based on a survey of sell-side research analysts that cover Celsion.

Celsion (NASDAQ:CLSNGet Rating) last announced its earnings results on Monday, May 16th. The biotechnology company reported ($1.82) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.99) by ($0.83). Celsion had a negative return on equity of 45.34% and a negative net margin of 5,110.80%. During the same quarter last year, the business posted ($1.35) EPS.

Several research firms have recently issued reports on CLSN. HC Wainwright began coverage on shares of Celsion in a research note on Tuesday, May 17th. They set a “buy” rating and a $16.00 price target for the company. StockNews.com began coverage on shares of Celsion in a research note on Saturday. They set a “hold” rating for the company.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Jane Street Group LLC raised its stake in Celsion by 181.8% during the third quarter. Jane Street Group LLC now owns 36,055 shares of the biotechnology company’s stock worth $33,000 after buying an additional 23,261 shares during the last quarter. FNY Investment Advisers LLC bought a new position in Celsion during the fourth quarter worth $35,000. Virtu Financial LLC bought a new position in Celsion during the fourth quarter worth $55,000. Renaissance Technologies LLC bought a new position in Celsion during the fourth quarter worth $59,000. Finally, Two Sigma Advisers LP bought a new position in Celsion during the third quarter worth $68,000.

Shares of NASDAQ CLSN traded down $0.01 during trading hours on Thursday, hitting $2.35. 26,983 shares of the stock were exchanged, compared to its average volume of 223,207. The company has a debt-to-equity ratio of 0.13, a quick ratio of 7.67 and a current ratio of 6.60. The company’s fifty day simple moving average is $3.83 and its two-hundred day simple moving average is $6.58. Celsion has a 1-year low of $2.23 and a 1-year high of $23.25.

Celsion Company Profile (Get Rating)

Celsion Corporation, a clinical stage biotechnology company, focuses on the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. Its product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer; and ThermoDox, a proprietary heat-activated liposomal encapsulation of doxorubicin, which is in development stage for various cancer indications.

See Also

Get a free copy of the Zacks research report on Celsion (CLSN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Celsion (NASDAQ:CLSN)

Receive News & Ratings for Celsion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celsion and related companies with MarketBeat.com's FREE daily email newsletter.